FDA moves toward easing restrictions on certain peptides BioPharma Dive FDA to weigh easing limits on unproven peptides BPC 157: Miracle Healing Peptide or Hidden Danger? RFK Jr. and the Perils of Peptides Washington Monthly The Peptide Boom Is Getting Out of Hand The Atlantic Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed